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AnticoagulationResults of the AMBER-AF registry were recently reported [1].
The authors find that 80% of patients with atrial fibrillation (AF)
and breast cancer and 85% without cancer were prescribed oral
anticoagulation (OA) at study outset and about 79% and 87%,
respectively, after completion of follow-up [1].
The authors emphasize that anticoagulation is underused in pa-
tients with AF and breast cancer but we find this to be a half-empty
take on an otherwise quite full glass. Anticoagulation underuse in
AF is a well-reported concern, with anticoagulation rates<70% in
the general population [2,3]. Similarly, after almost 3 years, 79%
of patients with cancer remained under OA(1% drop) [1]. Steep
discontinuation rates are a constant finding in studies in the gen-
eral population [4e7].
Of course, patients treated in a registry in tertiary healthcare in-
stitutions may receive more evidence-based treatment than other
subgroups but the AMBER-AF results are positive and a solid foun-
dation for randomized trials to optimize management of AF in pa-
tients with cancer/breast cancer.
To conclude, we understand the investigators’ disappointment
over use of anticoagulation [1] and we share their concern over
the higher stroke rates in patients with breast cancer. However,
the authors should be commended both for their effort and their
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